Serum Institute of India, the maker of the coronavirus vaccine Covishield, has been served a legal notice by AstraZeneca over vaccine supply delays.
Serum chief Adar Poonawalla told Business Standard that the Indian government is aware of the legal notice and is evaluating how to resolve the issue.
Also Read | UK to give AstraZeneca alternative to under-30 people amid blood clots concerns
He said that the dispute is over contractual obligations that Serum Institute is not able to fulfil due to its prioritisation of Indian supplies.
He also said the government's pause on major Covishield shipments to other countries and the "first claim" deal with India were difficult to explain abroad.
Also Read | India reports over 1.26 lakh new Covid-19 cases
Young relative of Fadnavis gets Covid-19 shot, triggers row
RIL increases oxygen supply 7 fold, Tata imports containers as shortage turns acute
Delhi records highest daily spike with 28,397 Covid-19 cases
Most Delhi hospitals have oxygen supply left for 8 to 12 hours: Sisodia
PM Modi to states: please ask migrants to stay put
PM to states: use lockdown as the last resort
Full lockdown in Maharashtra likely? Decision on Wednesday
Watch: BJP MP's 'shameless photoshoot' in front of vehicles carrying Covid corpses
Kerala sees highest daily spike with 19,577 Covid-19 infections
Economic interests cannot override human lives: Delhi HC to Centre on Oxygen shortage
Covid-surge: Jharkhand announces 8-day lockdown
Amazon, Flipkart suspend non-essential deliveries in Delhi due to lockdown
'Bad planning': Delhi HC pulls up Centre over vaccine wastage
Bharat Biotech ramps up Covaxin production to 70 crore doses per year
UGC-NET postponed due to Covid-19 resurgence
Maharashtra tightens curbs: grocery open from 7am to 11am, home delivery till 8pm
'Hollow, without substance, regrettable': Bengal CM on Centre's vaccine policy
India 'one of the most dangerous' countries for journalists
Kejriwal in isolation after wife Sunita tests Covid-19 positive
Rahul Gandhi tests positive for Covid-19